Cubist Appoints Robert J. Perez to Board of Directors
April 01 2014 - 8:00AM
Business Wire
Three Long-Serving Directors to Retire
Cubist (NASDAQ: CBST) today announced the appointment of Robert
J. Perez to its Board of Directors. Since 2012, Mr. Perez has
served as Cubist’s President and Chief Operating Officer (COO). The
Company also announced that in accordance with its Corporate
Governance Guidelines regarding term limits, three long-serving
Directors, Dr. Michael B. Wood, Dr. Martin Rosenberg, and J.
Matthew Singleton, each submitted a revocable resignation letter
thereby notifying the Company of their intent to retire from the
Board effective at the Company’s 2014 Annual Meeting of
Stockholders.
Robert J. Perez, Cubist (Photo: Business
Wire)
“Rob Perez is an outstanding leader with an impressive track
record of driving significant shareholder value for more than a
decade at Cubist, and we are delighted to have him join our Board,”
said Kenneth M. Bate, non-executive Chairman of the Board of
Directors at Cubist. “As President and COO, Rob has helped shepherd
the Company toward our Building Blocks of Growth through a careful
balancing of organic growth, disciplined M&A activity,
international expansion, and development of our people and culture.
We are entering a powerful growth cycle at Cubist, and we owe much
of this progress to Rob’s leadership and vision over the past
several years.”
Mr. Bate continued, “On behalf of the Board of Directors and
Cubist, I would like to thank Mike Wood, Marty Rosenberg, and Matt
Singleton for their long-standing service and important counsel
during a period of strong growth at Cubist. Their leadership and
dedication to the Company cannot be overstated, and we wish them
well in all future endeavors.”
Mr. Perez has served as our President and COO since July 2012.
From 2007 to 2012, Mr. Perez served as Executive Vice President and
COO. He joined Cubist in 2003 as Senior Vice President, Sales and
Marketing and then served as Senior Vice President of Commercial
Operations from 2004 to 2007. Prior to joining Cubist, Mr. Perez
served as Vice President of Biogen, Inc.'s CNS Business Unit where
he was responsible for leading the U.S. neurology franchise. From
1995 to 2001 he served as a Regional Director, Director of Sales,
and Avonex® Commercial Executive at Biogen. From 1987 to 1995, Mr.
Perez held various sales and marketing positions at Zeneca
Pharmaceuticals. Mr. Perez is a Director at AMAG Pharmaceuticals,
Inc. and from 2006 - 2009 served as a Director at EPIX
Pharmaceuticals, Inc. He is also a Trustee of the Dana-Farber
Cancer Institute and a Director of the California Healthcare
Institute, the Biomedical Science Careers Program, and a member of
the Board of Advisors of Citizen Schools of Massachusetts.
Mr. Perez received a B.S. from California State University, Los
Angeles and an M.B.A. from The Anderson School at UCLA.
About Cubist
Cubist Pharmaceuticals, Inc. is a global biopharmaceutical
company focused on the research, development, and commercialization
of pharmaceutical products that address significant unmet medical
needs in the acute care environment. Cubist is headquartered in
Lexington, Massachusetts, with a central international office
located in Zurich, Switzerland. Additional information can be found
at Cubist’s web site at www.cubist.com. Also, connect with Cubist
on Twitter @cubistbiopharma and @cubistcareers, LinkedIn, or
YouTube.
Forward-Looking Statements
This press release contains forward-looking statements. Any
statements contained herein which do not describe historical facts,
including but not limited to, statements regarding: our progress
against our Building Blocks of Growth five-year goals through 2017;
and the Company entering a powerful growth cycle, are
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements. Such risks and
uncertainties include, among others: our ability to achieve our
short-term and our long-term goals, including as a result of our
ability to continue to grow revenues from the sale of CUBICIN®
(daptomycin for injection), DIFICID® (fidaxomicin) and ENTEREG®
(alvimopan), generic and other competition, manufacturing issues,
our ability to successfully develop, gain marketing approval for
and commercially launch our product candidates for their planned
indications and on their expected timelines, and our ability to
discover, in-license or acquire new products and product
candidates; and those additional factors discussed in our most
recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission. We caution
investors not to place considerable reliance on the forward-looking
statements contained in this press release. These forward-looking
statements speak only as of the date of this document, and we
undertake no obligation to update or revise any of these
statements.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140401005492/en/
Cubist Pharmaceuticals, Inc.INVESTORS:Eileen C. McIntyre, 781-860-8533Vice
President, Investor
Relationseileen.mcintyre@cubist.comorMEDIA:Julie DiCarlo, 781-860-8063Senior Director,
Corporate Communicationsjulie.dicarlo@cubist.com